Investment Notes: Elyos
Blackbird's post explains why it led Elyos's Series A with PiLabs, YC and 468 Capital, profiling the AI phone-agent startup for trade businesses, its traction and its three founders.
Company
Oxford
Every investor coverage indicates participated in a round Oxford raised.
Companies Oxford acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Professor Mark Kendall | Lecturer (former) | @AuManufacturing (Sun 19 Jan 2025), @AuManufacturing (Mon 1 Jun 2020) |
Stories naming Oxford. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Blackbird's post explains why it led Elyos's Series A with PiLabs, YC and 468 Capital, profiling the AI phone-agent startup for trade businesses, its traction and its three founders.
Profile of Dr Kyle Turner launching the LaunchVic-funded Ochre pre-accelerator for First Nations founders, recalling his dental AI startup Pearlii and his role at a new First Nations venture fund.
First Nations-focused venture firm Ochre Ventures has closed the first tranche of its debut fund at $30m against a $100m goal, with PSG Holdings, MicroProse and Xylo Systems among five early investments.
Profile of Dr Kyle Turner, who is building Ochre, a LaunchVic-backed pre-accelerator for First Nations founders, and previously raised $3m-plus for dental AI startup Pearlii.
Also Startup Daily·LaunchVic
Profile of Pearlii founder Kyle Turner, whose Melbourne AI dental-checkup app followed a 2019 Dream Ventures pitch, tracing his journey from Dubbo to Oxford and the company's pivot to dental products.
AfterWork Ventures explains why it invested pre-seed in Samphire Neuroscience, a neurotech startup whose headband eases menstrual symptoms, alongside hardware accelerator HAX, profiling the Oxford-founded team and the women's health opportunity.
Also Startup Daily
Tenacious Ventures' investment note on its participation in Jupiter Ionics' AUD 2.5 million seed round; the startup develops carbon-neutral ammonia production using technology invented at Monash University.
Profile of Brisbane medtech firm Vaxxas on scaling its needle-free vaccine patch from prototype toward commercial manufacture, with pharma partner Merck and production specialist Harro Hofliger announced as collaborators.
Conference report from Melbourne where plant-based and conventional protein advocates debated. Fable Foods' funding round closed, and Michael Fox's earlier shoe startup Shoes of Prey is recalled as collapsed.
A University of New England-led project with UK firm BioCarbon Engineering will test drone and tractor seeding for cheaper revegetation of cotton farmland, backed by a $1.3 million government grant won by CRDC.
Opal Therapeutics partners with Massachusetts General Hospital on an HIV immunotherapy collaboration as human trials begin in London; the biotech counts Alloy Ventures, Alta Partners and GBS Ventures among its backers.